← Back to home

Non-muscle invasive bladder cancer (&#34;nmibc&#34;) unresponsive/intolerant to BCG

Clinical trials for Non-muscle invasive bladder cancer (&#34;nmibc&#34;) unresponsive/intolerant to BCG explained in plain language.

Never miss a new study

Get alerted when new Non-muscle invasive bladder cancer (&#34;nmibc&#34;) unresponsive/intolerant to BCG trials appear

Sign up with your email to follow new studies for Non-muscle invasive bladder cancer (&#34;nmibc&#34;) unresponsive/intolerant to BCG, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New bladder cancer drug gets first human test

Disease control Ongoing

This early-stage trial is testing a new drug called belzupacap sarotalocan (AU-011) for people with non-muscle-invasive bladder cancer. The drug is injected directly into the tumor, sometimes with a laser. The main goal is to see if this approach is safe and feasible. About 55 pa…

Matched conditions: NON-MUSCLE INVASIVE BLADDER CANCER (&AMP;#34;NMIBC&AMP;#34;) UNRESPONSIVE/INTOLERANT TO BCG

Phase 1 • Sponsor: Aura Biosciences • Aim: Disease control

Last updated Aug 08, 2026 00:03 UTC

Non-muscle invasive bladder cancer (&amp;#34;nmibc&amp;#34;) unresponsive/intolerant to BCG

Get alerted when new Non-muscle invasive bladder cancer (&amp;#34;nmibc&amp;#34;) unresponsive/intolerant to BCG trials appear

New bladder cancer drug gets first human test

Non-muscle invasive bladder cancer ("nmibc") unresponsive/intolerant to BCG

Get alerted when new Non-muscle invasive bladder cancer ("nmibc") unresponsive/intolerant to BCG trials appear